

SPECIAL ARTICLE

Salivary gland cancer: ESMO—European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up[†]

C. van Herpen^{1,2†}, V. Vander Poorten^{2,3,4†}, A. Skalova^{2,5†}, C. Terhaard^{2,6†}, R. Maroldi⁷, A. van Engen⁸, B. Baujat⁹, L. D. Locati¹⁰, A. D. Jensen^{11,12}, L. Smeele¹³, J. Hardillo¹⁴, V. Costes Martineau¹⁵, A. Trama¹⁶, E. Kinloch¹⁷, C. Even^{18,19} & J.-P. Machiels^{20,21}, on behalf of the ESMO Guidelines Committee*

¹Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands; ²Multidisciplinary Salivary Gland Society, Geneva, Switzerland; ³Department of Oncology, Section Head and Neck Oncology, KU Leuven, Leuven; ⁴Department of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium; ⁵Department of Pathology, Charles University, Faculty of Medicine in Plzen, Plzen, Czech Republic; ⁶Department of Radiotherapy, University Medical Center, Utrecht, The Netherlands; ⁷Department of Radiology, ASST Spedali Civili Brescia—University of Brescia, Brescia, Italy; ⁸Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands; ⁹Department of Otorhinolaryngology, Head and Neck Surgery, Sorbonne Université Hôpital Tenon, Assistance Publique Hôpitaux de Paris, Paris, France; ¹⁰Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ¹¹Faculty of Medicine, Philipps-University Marburg, Marburg; ¹²Department of Radiation Oncology, University Hospitals Gießen and Marburg (UKGM) Ltd, Gießen, Germany; ¹³Department of Head and Neck Oncology and Surgery, Antoni van Leeuwenhoek Ziekenhuis & Amsterdam UMC, Amsterdam; ¹⁴Department of Otorhinolaryngology, Head and Neck Surgery, Erasmus University Medical Center, Rotterdam, The Netherlands; ¹⁵Department of Pathology, CHU Montpellier, Montpellier, France; ¹⁶Evaluative Epidemiology, Department of Research, Fondazione IRCSS Istituto Nazionale dei Tumori, Milan, Italy; ¹⁷Salivary Gland Cancer UK, London, UK; ¹⁸Head and Neck Department, Gustave Roussy, Paris; ¹⁹French Network for Rare Head and Neck Cancers, Paris, France; ²⁰Service d'Oncologie Médicale, Institut Roi Albert II, Cliniques Universitaires Saint-Luc, Brussels; ²¹Institut de Recherche Clinique et Expérimentale, Université Catholique de Louvain (UCLouvain), Brussels, Belgium



Available online 2 November 2022

Key words: ESMO—EURACAN Clinical Practice Guideline, diagnosis, treatment, follow-up, salivary gland cancer

INCIDENCE AND EPIDEMIOLOGY

Major salivary gland cancers (SGCs) comprise 5% of head and neck cancers in Europe. The worldwide crude and age-adjusted incidence rates are 0.69 and 0.57 cases per 100 000 people per year, respectively, with 53 583 new patients in 2020. In Europe, crude and age-adjusted incidence rates are 1.3 and 0.67 cases per 100 000 people per year, respectively, with 9917 new patients in 2020.¹ Data for minor SGCs are limited, but the RARECARENet project estimated the crude incidence of minor salivary gland-type cancers of the head and neck to be 0.4 cases per 100 000 people in the 2000–2007 diagnosis period; minor SGCs have a slight predominance in males and incidence is highest in the elderly (>65 years).²

History of head and neck cancer and cervicofacial radiotherapy (RT) have both been associated with an increased risk of major SGC [odds ratio (OR) 17.06, 95% confidence interval (CI) 4.34–67.05 and OR 31.74, 95% CI 2.48–405.25, respectively].^{3,4} Industries such as cereal and other crop

production, furniture manufacturing, interurban road transport and industrial cleaning have also been associated with an increased risk of major SGC.^{3–5} Smoking only seems to increase the risk of developing major SGCs other than mucoepidermoid carcinoma (MEC) (OR 5.15, 95% CI 2.06–12.87)⁶; however, ionising radiation is the only well-established risk factor.^{7,8}

SGCs include >20 distinct histological subtypes. Given their rarity and heterogeneity, population-based epidemiological studies providing incidence rates according to histology are limited.

SGC typically occurs in the sixth and seventh decades of life and has a male predominance²; however, age at diagnosis and gender predominance vary by histology. MEC, adenoid cystic carcinoma (AdCC) and acinic cell carcinoma (AcCC) tend to occur at an earlier age than adenocarcinoma and squamous cell carcinoma (SCC). MEC, AdCC and AcCC are more common in females up to ~50 years of age; however, incidence of AdCC and AcCC is similar for females and males at older ages, whereas MEC has a higher incidence rate among older males.⁷ The ratio of tumour diagnoses in parotid, submandibular, minor and sublingual subsites is 100:10:10:1, and the proportion of malignant tumours at these sites is 20%, 50%, 50% and 80%, respectively.⁹

SGC incidence has not increased between 1995 and 2007 in Europe¹⁰ or between 1995 and 2010 in the United States.⁷

*Correspondence to: ESMO Guidelines Committee, ESMO Head Office, Via Geneva 4, CH-6900 Lugano, Switzerland

E-mail: clinicalguidelines@esmo.org (ESMO Guidelines Committee).

Twitter handle: @myESMO, @rarecancer, @carlavanherpen

[†]Approved by the ESMO Guidelines Committee: October 2022.

[‡]These authors contributed equally.

2059-7029/© 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

The 5-year relative survival rate (estimated as the ratio of observed to expected survival in the general population, matched by age, sex, calendar year and geographical area) for patients with major SGC is 63% (95% CI 62% to 63.7%) in Europe.¹⁰ This decreases with age, from ~90% (95% CI 91% to 97%) in patients aged <25 years, to 70% (95% CI 69% to 71%) in patients aged 25–64 years and 53% (95% CI 52% to 55%) in those aged >65 years. Five-year relative survival is higher in females (72%, 95% CI 71% to 74%) than in males (55%, 95% CI 54% to 56%). Furthermore, 5-year relative survival differs across European regions, with the highest rate of 74% (95% CI 71% to 78%) reported in Nordic countries (Finland, Iceland, Norway) and the lowest rate of 52% (95% CI 50% to 54%) reported in Eastern European countries (Bulgaria, Czech Republic, Estonia, Latvia, Lithuania, Poland, Slovakia). SGC relative survival has not improved in Europe between 1999 and 2007.²

The 5-year relative survival rate for minor salivary gland-type cancers of the head and neck is 67% and is higher in females than in males. Five-year survival rates are highest in children (>90%) and patients aged <25 years, and then decrease to 60% in patients aged >65 years. In Europe during the period 1999–2007, 5-year survival remained stable and was highest in Nordic countries (84%) and lowest in Eastern European countries (55%).²

DIAGNOSIS, PATHOLOGY AND MOLECULAR BIOLOGY

SGC should be classified according to the World Health Organization (WHO) Classification of Head and Neck Tumours.¹¹ Including both benign and malignant tumours, there are over 30 distinct salivary gland tumour types in the latest WHO classification system (see [Supplementary Table S1](https://doi.org/10.1016/j.esmoop.2022.100602), available at <https://doi.org/10.1016/j.esmoop.2022.100602>, for classification of the malignant tumour types).

Diagnostic work-up

The symptoms of SGC depend on tumour location. Symptoms that should prompt consideration of SGC include pain in the face or mouth, an externally or submucosally growing lump or (facial) nerve paralysis.

Cytology or histology is mandatory. Ultrasound-guided salivary gland fine-needle aspiration (FNA) cytology has become the accepted minimally invasive method for evaluating parotid and submandibular gland tumours preoperatively. This can distinguish malignant from benign disease in 90% of cases if examined by a pathologist experienced in salivary gland disease.¹² The Milan system for reporting salivary gland cytopathology is recommended. It facilitates standardised reporting and links each diagnostic category to a risk of malignancy (ROM); risks were recently confirmed in a large meta-analysis.¹³ The Milan system facilitates ROM-associated therapeutic approaches, e.g. initial treatment can be intensified when high-grade malignancy is suspected (one study reported 99% diagnostic accuracy¹⁴) (see

[Supplementary Table S2](https://doi.org/10.1016/j.esmoop.2022.100602), available at <https://doi.org/10.1016/j.esmoop.2022.100602>).¹²

If FNA is non-diagnostic or if the clinical situation requires more information on histotype, core needle biopsy, while more demanding and with a slightly increased risk of complications,¹⁵ has less inadequate sampling (risk ratio 0.85) and a higher diagnostic yield than FNA.¹⁶ It is thus an accepted next step in the diagnostic work-up.¹⁷

Open biopsies should be avoided in major salivary gland lesions due to the risk of complicating definitive surgical treatment and the risk of spillage, with the exception of skin ulcerating tumours. For minor salivary gland tumours, an experienced surgeon should take a biopsy of the tumour and surrounding stroma.¹⁸ Incisional biopsy is recommended for submucosally extending tumours, and an incisional or forceps biopsy should be taken for ulcerating lesions.

Ultrasound, computed tomography (CT), magnetic resonance imaging (MRI) and [¹⁸F]2-fluoro-2-deoxy-D-glucose—positron emission tomography (FDG—PET) are the imaging techniques most commonly used to assess lesions in the major salivary glands, with MRI being the preferred modality (see [Figure 1](#)). Diagnostic imaging techniques are described in Section 1 of the [Supplementary Material](#), available at <https://doi.org/10.1016/j.esmoop.2022.100602>.

Histological tumour type and molecular biology

The SGC histological type essentially defines its biological behaviour, which influences prognosis and patterns of recurrence, and thus clinical management.

Some SGC types, such as basal cell adenocarcinoma, low-grade MEC, intraductal carcinoma and conventional AcCC, are indolent, with high risk of locoregional recurrence but low rates of nodal involvement and distant metastases.¹⁹

Immunohistochemistry (IHC) on the surgical specimen provides supplementary visualisation of cell compartments and cell populations, thus improving SGC taxonomy. The role of molecular diagnostics in SGC is evolving. Many monomorphic SGCs are now known to harbour defining balanced translocations, some of which are readily evaluable on paraffin-embedded materials either by FISH, RT–PCR or next-generation sequencing (NGS).²⁰ Recently, NGS has provided significant input on the molecular characterisation of SGC subtypes, improving diagnostic differentiation between morphologically similar tumour types and also identifying novel driver pathways that determine tumour biology and which may be amenable to targeted therapy [see European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of Molecular Targets (ESCAT) for further details in [Supplementary Table S3](https://doi.org/10.1016/j.esmoop.2022.100602), available at <https://doi.org/10.1016/j.esmoop.2022.100602>]. SGC histological subtypes are described in detail in Section 2 of the [Supplementary Material](#), available at <https://doi.org/10.1016/j.esmoop.2022.100602>. Key molecular alterations in SGC are described in [Supplementary Table S4](#), available at <https://doi.org/10.1016/j.esmoop.2022.100602>.




Figure 1. Work-up of major salivary gland nodules. Purple: general categories or stratification; white: other aspects of management.

AdCC, adenoid cystic carcinoma; CNB, core needle biopsy; CT, computed tomography; FDG-PET-CT, [¹⁸F]2-fluoro-2-deoxy-D-glucose-positron emission tomography-computed tomography; FNA, fine-needle aspiration; MRI, magnetic resonance imaging.

^aCNB considered when FNA is non-diagnostic or if more histological information is required.

Recommendations

- Classification should be carried out according to the WHO Classification of Head and Neck Tumours [I, A].
- Clinical examination and pathological confirmation are mandatory [IV, A].
- FNA should be used for screening; if inadequate, core needle biopsy can be a next step [III, A].
- FNA results should be reported according to the Milan classification, including a defined ROM and suggested therapeutic approaches [IV, A].
- For minor salivary gland tumours, an experienced surgeon should take a biopsy of the tumour and surrounding stroma. For submucosally extending tumours, an incisional biopsy, and for ulcerating lesions an incisional or forceps biopsy should be taken [IV, A].
- When malignancy is suspected, MRI is the preferred imaging modality [IV, A].
- Contrast-enhanced CT is mostly limited to patients in whom MRI is contraindicated [IV, B].
- Regardless of the imaging technique used, the study should be extended to include the ipsilateral and contralateral neck levels or integrated with ultrasound examination of neck lymph nodes [III, A].
- FDG-PET-CT is recommended in high-grade SGC for the detection of distant metastases [III, A].

- IHC and molecular testing should be used as supplementary tools when appropriate [IV, A]. Confirmation of androgen receptor and human epidermal growth factor receptor 2 (HER2) status is mandatory in salivary duct carcinoma and adenocarcinoma not otherwise specified (NOS) with distant metastases [III, A; ESCAT score: II-B].
- Analysis for *NTRK* fusion with NGS or whole genome sequencing is mandatory for differential diagnosis of secretory carcinoma and AcCC [III, A; ESCAT score: I-C].
- NGS or whole genome sequencing (or whole exome sequencing) is suggested in recurrent or metastatic (R/M) disease for all tumour subtypes, as actionable mutations or fusion genes can be identified in 40%-50% of patients [V, C].

STAGING AND RISK ASSESSMENT

Staging

Clinical classification [cTNM (clinical tumour-node-metastasis)] should be carried out before treatment by the referring physician during initial patient evaluation using the Union for International Cancer Control (UICC) TNM eighth edition staging classification.²¹ Preoperative diagnostics are mainly based on imaging methods and

pathological findings, especially FNA. Pathological staging is carried out after surgical resection of the primary tumour. There is currently no clear recommendation on differential staging of intraparotid versus cervical nodal metastases; findings from a recent study suggest that these differences should be addressed in future editions of the TNM classification.²²

Pathological report and staging

For correct management of major SGC, the pathological report should follow the International Collaboration on Cancer Reporting guidelines.²³ Operative procedure; specimens submitted; tumour site, focality and dimensions; histological tumour type and grade; perineural invasion; lymphovascular invasion; extent of invasion and margin status are required (see Section 3 of the [Supplementary Material](https://doi.org/10.1016/j.esmoop.2022.100602), available at <https://doi.org/10.1016/j.esmoop.2022.100602>).²³

The UICC pathological TNM (pTNM) staging system for SGC of the major salivary glands is presented in [Supplementary Table S5](https://doi.org/10.1016/j.esmoop.2022.100602), available at <https://doi.org/10.1016/j.esmoop.2022.100602>. Minor SGCs are staged similarly to SCC, according to the site in which they arise (e.g. oral cavity, pharynx, sinuses, etc.).

Recommendations

- Clinical classification should be carried out before treatment and pTNM should be carried out after surgical resection using the UICC eighth edition staging classification [I, A].
- Intra-operative frozen sections can be indicated to evaluate margins of resection, perineural invasion and lymph nodes, but only if the result is expected to alter management at the time of surgery [IV, B].
- The pathological report should follow the International Collaboration on Cancer Reporting guidelines [III, A].

MANAGEMENT OF LOCAL AND LOCOREGIONAL DISEASE

SGCs are a rare and complicated subgroup of head and neck cancers. As such, local/locoregional disease should be managed by expert surgeons, radiation oncologists, medical oncologists and other specialists working as a multidisciplinary team in specialised head and neck units, such as the centres that are designated members of the European Reference Network on Rare Adult Solid Cancers.

Proposed treatment algorithms for the treatment of parotid, minor salivary and sublingual gland, and submandibular gland cancer, are shown in [Figures 2, 3 and 4](#), respectively.

Surgery

Surgical management of the primary in parotid gland cancer. The treatment of parotid gland cancer is based on complete surgical excision with free margins.²⁴ The

difficulty of this surgery lies in achieving free margins without functional and aesthetic sequelae. Revision surgery following an unexpected post-operative diagnosis of malignancy carries a great risk to an already dissected facial nerve; therefore, every effort should be made to identify malignancy preoperatively, allowing for immediately adequate surgical removal.²⁵ It is imperative, if preoperative MRI, FNA or core needle biopsy suggests malignancy, to warn the patient of a possibly more extensive procedure. In case of extraparotid or facial nerve extension, an extended surgery sacrificing these elements [e.g. seventh nerve (nVII), infratemporal fossa, mandible, skin] with possible reconstruction must be considered. Functional or aesthetic disorders arising from resection should be considered during treatment planning.²⁴ Resectability should be assessed in a multidisciplinary team meeting, bearing in mind that surgery, if possible, is the optimal treatment. A cancer should be considered unresectable if macroscopic tumour is likely to be left behind.

The reference procedure is a total parotidectomy. For low-grade, early-stage (cT1-T2N0) tumours in the superficial lobe, a superficial parotidectomy can suffice, especially if malignancy is a post-operative discovery on the definitive histology. For advanced-stage (all but cT1-T2N0) and/or preoperatively known intermediate- or high-grade tumours, a total parotidectomy is preferable. No consensus exists in the literature on how many millimetres thick a margin must be to be considered 'free'.

The presence or absence of facial nerve paralysis before surgery influences the choice of procedure: it is logical to try to preserve the facial nerve if there is no preoperative paralysis and to sacrifice it in case of preoperative paralysis.²⁴ In the absence of preoperative paralysis and in case of intra-operative macroscopic invasion of the facial nerve, sacrifice or preservation of the nerve is decided on a case-by-case basis, depending on the histology of the tumour and extent of invasion of the nerve, as well as the age and wishes of the patient. It is important to collect as much information as possible about the tumour before surgery, discuss scenarios with the patient and be able to do a graft during the ablative procedure. A remote dissection of the nerve branches with an extended resection and frozen section analysis of the nerve section limits may be necessary, especially in AdCC, which is characterised by tumour extensions along and in nerves.²⁶ Preoperative facial paralysis is a major negative prognostic factor.²⁴ It imposes a wide surgery with often unsatisfactory excisional limits. Addressing the nerve deficit during resection is the appropriate therapeutic approach.^{24,27}

Surgical management of the primary in minor SGC and cancer of the sublingual gland. Minor SGC, a rare entity, may arise in all mucous membranes of the head and neck (including the nasal cavity, nasopharynx, oropharynx, hypopharynx, cervical oesophagus, larynx, trachea and oral cavity). Cancer of the sublingual gland is 10 times less frequent than minor SGC.⁹




Figure 2. Treatment algorithm for parotid gland cancer. Purple: general categories or stratification; red: surgery; dark green: radiotherapy; white: other aspects of management; blue: systemic anticancer therapy.

ChT, chemotherapy; CNB, core needle biopsy; END, elective neck dissection; ENI, elective neck irradiation; FNA, fine-needle aspiration; ND, node dissection; nVII, seventh nerve; RT, radiotherapy.

*Definition of high-grade tumours is described in Section 1 of the [Supplementary Material](https://doi.org/10.1016/j.esmooop.2022.100602), available at <https://doi.org/10.1016/j.esmooop.2022.100602>.

Surgery is the mainstay of treatment for primary resectable disease with the traditional open approach being the most widely used, although endoscopic and robot-assisted approaches have recently been described.²⁸ In a series of 450 patients with minor SGC, multivariate analysis showed advanced clinical stage and unfavourable histological subtype to be associated with poor disease-specific survival.²⁹ This was confirmed in a large Surveillance, Epidemiology and End Results (SEER) database study of 1426 patients with minor SGC of the oropharynx.³⁰ It is generally accepted that a 1-cm free margin is adequate in most tumours; however, it is often the case that only millimetric margins are achievable. AdCC is particularly known for perineural spread (as described earlier), requiring detailed surgical planning and wide margins, including resection of bony structures.²⁴

Surgical management of the primary in submandibular gland cancer. The most common submandibular gland malignant tumour type is AdCC.^{31,32} Tumours confined within the submandibular gland require resection of the gland and the surrounding level Ib lymph nodes to ensure

negative margins. In case of high-grade malignancy without clinical evidence of cervical lymph node involvement, selective neck dissection involving level I, II and III lymph nodes is standard procedure as the prevalence of cervical lymph node metastasis in submandibular gland malignancies is high, exceeding that of the parotid malignancies.^{24,32,33} Careful surgical planning is needed for AdCC, as clear margin surgery may require resection of important structures such as the lingual, hypoglossal and marginal mandibular nerves, floor of the mouth muscles and the skin. Although the risk of nodal metastasis in AdCC is low, this tumour has a propensity for infiltrating the adjacent lymph nodes and perineural spread.^{24,31,32,34} While it can be difficult to distinguish between direct invasion and embolic lymph node metastasis, some studies have identified a higher nodal spread than expected.³⁵ Elective neck dissection (END) for submandibular gland malignancies should be planned based on cytological and radiological findings. Whenever malignancy is suspected, frozen section analysis can dictate extension of surgery locally and to involve at least level Ib but most frequently level I, II and III lymph nodes.³²




Figure 3. Treatment algorithm for minor or sublingual SGC. Purple: general categories or stratification; red: surgery; dark green: radiotherapy; white: other aspects of management; blue: systemic anticancer therapy.

ChT, chemotherapy; END, elective neck dissection; ND, node dissection; RT, radiotherapy; SGC, salivary gland cancer.

*Definition of high-grade tumours is described in Section 1 of the [Supplementary Material](https://doi.org/10.1016/j.esmooop.2022.100602), available at <https://doi.org/10.1016/j.esmooop.2022.100602>.

Management of the cN+ neck in salivary gland malignancies.

The reported incidence of positive neck nodes in parotid carcinomas varies between 10% and 40% and they occur more frequently in patients with high-grade malignancy, advanced T status, facial nerve involvement and extraglandular invasion.^{36,37} The most frequently involved lymph node levels are II, III and IV³⁸; however, involvement of levels I and V is also non-negligible.^{35,39} When carrying out therapeutic neck dissection for clinically or radiologically positive lymph nodes (cN+), the recommendation is to carry out a comprehensive neck dissection of levels I-V.^{35,39}

The incidence of lymph node metastasis for submandibular carcinomas at initial presentation is around 8%-33%.⁴⁰ Positive lymph nodes are often found in level I followed by levels II and III, although all lymph nodes can be involved with the possibility for skip metastases in levels IV and V. Some series have even shown positive lymph node involvement of 40% and 25% in levels IV and V, respectively, warranting a level I-V neck dissection for submandibular gland carcinomas with cN+ disease.³¹

For minor SGC, the same applies, but depending on the origin of the primary, lymph nodes outside the neck may be involved that are relatively inaccessible for surgery, such as retropharyngeal or mediastinal nodes.

END for the cN0 neck in parotid gland carcinoma. In a cN0 neck parotid gland carcinoma with clinical and histopathological factors indicating a 15%-20% chance of occult regional metastasis, END is strongly recommended. Clinical prognostic factors for pathologically positive lymph nodes (pN+) are age >54 years, pain, nVII dysfunction and >T2 status.^{41,42} A study using END in T1-T2 N0 patients reported a cN0 pN+ rate of 17%.⁴³ Histopathological factors (that unfortunately only become clear once the primary is resected) include histological type, intermediate- or high-grade tumour, extraglandular soft tissue invasion and lymphatic invasion.^{40-42,44,45} Histological types with a high prevalence (>50%) of cN0 pN+ disease are salivary duct carcinoma, undifferentiated carcinoma, adenocarcinoma NOS, high-grade MEC, SCC and high-grade transformed

AdCC.^{36,40} AcCC and low-grade MEC were previously considered to have low pN+ rates but routine ENDs have revealed higher than expected rates, especially for high-grade AcCC.^{36,38,39,43,44,46} Regarding the best treatment strategy, some clinicians use END followed by post-operative RT, while others prefer to use elective neck irradiation (ENI) (see RT section).^{41,45,47-49}

Some clinicians propose a routine END for every patient with suspected or known parotid gland cancer; reported rates of cN0 pN+ range from 22% to 45% in series where all patients underwent END.^{36,43,50,51} The lymph node levels to address are II, III and IV.^{39,40} A significant proportion (53%-80%) of patients with pN+ disease on neck dissection will also have metastatic deposits in the 'first echelon' intra-parotid lymph nodes (see earlier Surgical management of the primary in parotid gland cancer section).^{24,40,52} In one study, 1-11 parotid lymph nodes were retrieved, with 80% of parotid nodes involved in cN0 pN+ patients.³⁸ There is still no direct evidence that resection of these nodes increases locoregional control. Taken together, three scenarios exist:

1. Low risk of occult nodal disease (T1-T2 tumours, low-grade tumours, young patients)
 - After resection of the primary, a watch-and-wait policy to the neck can be defended³⁹
 - Most clinicians will carry out a level II dissection with frozen section, converting into a comprehensive neck dissection in the rare pN+ cases,²⁴ but leaving the neck untreated if pN0
 - Systematic END^{36,38,43,50,51}
2. Risk factors for cN0 pN+ discovered at histology of parotidectomy
 - ENI is recommended^{41,49}
3. High risk of occult nodal disease preoperatively
 - END (levels II, III and IV) and post-operative neck RT based on pathology. Level I (anteriorly located primary) and level V (large tumour located in the parotid tail with increased risk of spread to level V) dissection on indication^{39,45}
 - ENI, especially if adjuvant RT for the primary tumour is already likely^{41,48,49}
 - Level II dissection, extended to a comprehensive neck dissection if cN0 pN+ on frozen section. If no pN+, ENI to the neck follows the findings in the pathology report of the resected primary²⁴

END for the cN0 neck in minor SGC. For minor SGC, when the neck is surgically entered as an approach to the primary, it is logical to also address the neck surgically. The occult metastatic rate for laryngeal, sinonasal, external acoustic meatus and lacrimal gland origin is too low to justify END. In oral cavity (levels I, II, III and IV) and oropharyngeal (levels II, III and IV) minor SGC, and in high-grade MEC and AdCC, the occult rates largely exceed 20% and END is indicated.^{53,54} END is frequently advocated for all high-stage and high-grade tumours. In a recent French study, however, no benefit in terms of event-free survival was demonstrated when comparing patients with cN0 AdCC

undergoing END with those who did not, except when the site of origin was the oral cavity. In this series, the majority (58%) of 322 cases were of minor salivary gland origin.⁵⁵ In a large series of 3005 patients with MEC of the oral cavity and oropharynx, END was associated with a survival benefit for patients with high-grade and clinical stage T3-4 disease.⁵⁶

END for the cN0 neck in submandibular gland carcinoma.

For preoperatively known submandibular gland cancers with otherwise cN0 neck, inclusion of the submandibular gland in a selective neck dissection (levels I, II and III) is considered the standard procedure, revealing occult metastasis rates of 21%-23%.^{33,57} For completely intra-glandular tumours, if preoperatively certain to not be high grade, resection of the gland and the surrounding level Ib lymph nodes may suffice.³²

RT

Post-operative RT for SGC. Historically, SGCs were considered radioresistant. There are no randomised studies comparing surgery alone versus surgery combined with post-operative RT. Nevertheless, many retrospective studies have reported beneficial outcomes with a combined approach in patients with advanced disease and negative prognostic factors for locoregional control.

Based on literature using matched pair analysis or large retrospective cohort studies described in Section 4 of the [Supplementary Material](https://doi.org/10.1016/j.esmoop.2022.100602), available at <https://doi.org/10.1016/j.esmoop.2022.100602>, post-operative RT at the primary tumour region is recommended in case of T3-T4 disease, high/intermediate-grade disease, close or incomplete resection margins and/or perineural growth.^{45,58} The use of intensity-modulated RT (IMRT) or volumetric modulated arc therapy (VMAT) is recommended. For parotid gland cancer invading the deep lobe, the infratemporal fossa and the parapharyngeal space should be included in the field. After incomplete resection, a dose of 33 × 2 Gy is described for the primary tumour region plus a 1 cm margin, with 30 × 2 Gy after a clear resection.^{45,58} In case of extensive perineural invasion the nerve pathway to the base of the skull should be delineated.⁵⁹

Indications for ENI (25 × 2 Gy over 5 weeks) are the same as the indications for END. In general, ENI is indicated in case of T3-T4 cN0 tumours and high- or intermediate-grade subtypes, and also depends on the primary site.⁵⁸ The ipsilateral neck node levels II and III should be treated in parotid gland tumours and ipsilateral levels I, II and III in submandibular gland tumours. Bilateral ENI is indicated for tumours crossing the midline. For minor SGC, the highest risk for subclinical neck disease is a pharyngeal location, high-grade disease and T3-T4 tumours. Ipsilateral ENI is recommended for levels I, II and III.

Post-operative RT is indicated for all cases of pN+ neck. A dose of 30 × 2 Gy is recommended for the involved level, and 33 × 2 Gy in case of extranodal disease. For the ipsilateral elective levels I-V, a dose of 25 × 2 Gy is recommended.⁵⁸




Figure 4. Treatment algorithm for submandibular gland cancer. Purple: general categories or stratification; red: surgery; dark green: radiotherapy; white: other aspects of management; blue: systemic anticancer therapy.

ChT, chemotherapy; CNB, core needle biopsy; FNA, fine-needle aspiration; ND, node dissection; RT, radiotherapy.

*Definition of high-grade tumours is described in Section 1 of the [Supplementary Material](https://doi.org/10.1016/j.esmoop.2022.100602), available at <https://doi.org/10.1016/j.esmoop.2022.100602>.

Combining post-operative RT with chemotherapy. There are no large series analysing the role of combined chemotherapy (ChT) and RT in the post-operative setting in SGC. In the phase II Radiation Therapy Oncology Group (RTOG) 1008 study (NCT01220583) both scenarios are being compared, but no results are available yet.

Combining post-operative ChT with RT in major SGC has been evaluated retrospectively using data from the US National Cancer Database. The addition of ChT was restricted to late-stage tumours with adverse features and did not result in a survival benefit.⁶⁰ In a retrospective cohort study, platinum-based post-operative chemoradiotherapy ($n = 37$) was compared with post-operative RT only ($n = 103$). In the chemoradiotherapy group, more patients had N+ disease, positive surgical margins and perineural invasion. In multivariate analysis, progression-free survival (PFS) was not improved by the addition of ChT.⁶¹ Comparable results were reported in a subset of patients with high-risk SGC.^{62,63} In an ongoing phase III, multicentre, randomised, open-label, French study, post-operative or primary RT alone is being compared with concomitant RT plus cisplatin on days 1, 22 and 43 for SGC and nasal cancer. No results are available yet.⁶⁴

The level of evidence for combining ChT with RT is low and this treatment is not recommended outside of a clinical study.

Primary RT for unresectable SGC. The primary treatment for SGC without distant metastasis is surgery with post-operative RT when indicated; however, curative primary RT is indicated for patients with functionally unresectable disease or who are unsuitable for surgery due to comorbidities.

Taking locoregional control, survival and complications into account, the treatment options are photon treatment or particle treatment with protons, neutrons or carbon ions (C12). In most institutes, primary photon therapy up to 70 Gy is still applied. Particle treatment, particularly C12 and especially for AdCC and tumours involving the base of the skull, may be an alternative with a potentially higher locoregional cure rate compared with photons; however, these treatment options have limited availability. The literature supporting the use of particle treatment is described in Section 5 of the [Supplementary Material](https://doi.org/10.1016/j.esmoop.2022.100602), available at <https://doi.org/10.1016/j.esmoop.2022.100602>.

No randomised studies have been carried out to compare primary treatment with chemoradiotherapy versus RT alone. Most published studies report small series with different histological subtypes, using a variety of ChT regimens.⁶²

There is currently no evidence to support the combination of particle therapy and simultaneous ChT in SGC.⁶⁵

Recommendations

Surgical management of the primary: parotid gland cancer

- The reference procedure is total parotidectomy [IV, A].
- For low-grade tumours, especially post-operatively discovered, a superficial parotidectomy can be considered sufficient [IV, A].
- If the nVII is not infiltrated or grossly encased by tumour, the nerve should be preserved [IV, A].
- A preoperatively paralysed nVII requires nVII resection and primary reconstruction and/or reanimation procedures [IV, A].
- It is important to collect as much information as possible about the tumour before surgery, discuss scenarios with the patient and be able to do a graft during the ablative procedure [IV, A].

Surgical management of the primary: submandibular gland cancer

- Malignant tumours confined within the submandibular gland require at least resection of the gland and the surrounding level Ib lymph nodes [IV, A].
- In case of high-grade malignancy without clinical evidence of cervical lymph node involvement, including the gland in a selective neck dissection involving levels I, II and III is indicated [IV, A].

Surgical management of the cN+ neck in SGC

- Patients with positive lymph nodes (clinical or radiological) should undergo a comprehensive lymph node dissection involving levels I-V [IV, A].

Surgical management of the cN0 neck in parotid gland cancer

- Patients at low risk for cN0 pN+ before surgery (T1-T2, low grade, <54 years of age) have three options: (i) watch-and-wait; (ii) selective level II dissection (followed by watch-and-wait if pN0 or extend neck dissection to levels I-V if pN+); (iii) END to levels II, III and IV [IV, B].
- Patients with risk factors for cN0 pN+ discovered post-operatively should undergo ENI (cN0 at least levels II and III unilaterally; pN+ levels I-V) [IV, B].
- Patients at high risk for cN0 pN+ (T3-T4, high grade, >54 years of age) have three options: (i) selective level II dissection (followed by watch-and-wait if pN0 or extend neck dissection to levels I-V if pN+); (ii) END to levels II, III and IV (followed by watch-and-wait if pN0 or RT to levels I-V if pN+); (iii) ENI to levels I-V [IV, B].

Surgical management of the cN0 neck in minor SGC

- As a general rule, END should be carried out when the neck is entered as an approach to the primary or for reconstruction [IV, B].
- In tumours of laryngeal, sinonasal, external acoustic meatus and lacrimal gland origin, pN+ rates are too low to justify END [IV, B].
- For oral cavity, oropharynx, T3-T4 and high-grade tumours, END or ENI should be carried out. Levels depend

on tumour location and are comparable with treatment for cN0 head and neck SCC [IV, B].

Surgical management of the cN0 neck in submandibular gland cancer

- Including the gland in a selective neck dissection involving levels I, II and III is indicated, unless the tumour is intraglandular and if low-grade histology is proven (in which case resection of the gland and level Ib lymph nodes may suffice) [IV, B].

Post-operative or primary RT or chemoradiotherapy

- Post-operative local RT is recommended for T3-T4 and intermediate/high-grade tumours and in cases with close resection margins (1-5 mm; 30 × 2 Gy), incomplete resection margins (33 × 2 Gy) or perineural growth [IV, A].
- Post-operative regional RT is recommended for cases with pN+ (30 × 2 Gy) and extranodal extension (33 × 2 Gy). Unilateral ENI (25 × 2 Gy) is recommended based on the same inclusion criteria as for END [IV, A].
- There is no proof of a beneficial effect of adding ChT to post-operative RT of the primary tumour and neck [IV, C].
- Curative primary RT is indicated for patients with functionally unresectable disease or who are unsuitable for surgery due to comorbidities [IV, B].
- Primary IMRT/VMAT photon RT up to 35 × 2 Gy to the primary tumour and positive neck nodes with ENI with equal indications as for primary surgery may result in ~50% locoregional control [IV, B].
- Primary particle treatment, namely C12, may result in higher locoregional control rates compared with photon RT (but with limited availability) [IV, C].
- There is no proof of a beneficial effect of adding ChT to primary RT in patients with unresectable SGC or those who are unsuitable for surgery [IV, C].

MANAGEMENT OF LOCALLY RECURRENT AND METASTATIC DISEASE

RT

RT may be used for the management of locally recurrent disease and/or for palliation.

RT for recurrent disease. Local recurrence within the high-dose area following initial RT remains a challenge. When surgery is not an option, systemic treatments (either ChT or targeted agents) offer limited benefit with very moderate overall response rates and are therefore rarely successful in alleviating local symptoms. Before the introduction of particle therapy, re-irradiation with photons was used with utmost caution, especially in anatomically challenging sites. Meanwhile, three groups have shared their experience of re-irradiation using scanned C12 in SGC,⁶⁶⁻⁶⁸ reporting 1-year and 2-year overall survival (OS) rates of up to 90% and 64%, respectively, although late toxicities were observed. Based on these studies, re-irradiation with C12 appears

feasible with response rates of around 60% and moderate toxicities in heavily pre-treated patients; however, C12 has limited availability in Europe. Protons are becoming more widely available, but evidence is lacking to support the added value. Further dose escalation should be employed cautiously. There is no evidence to support the combination of re-irradiation and ChT for primary treatment of SGC.

RT for palliation. In the RTOG 8502 study, an RT regimen of 4×3.7 Gy over 2 days was repeated in cycles of 4 weeks. Seven out of 75 patients had salivary gland histology. Palliative response was observed in 65% of patients, significantly correlating with the number of cycles.⁶⁹ For palliative RT of head and neck cancer, the 'Christie scheme' (16×3.125 Gy over 4 weeks) resulted in a 45% complete response rate and 28% partial response rate.⁷⁰ This schedule may also be considered in patients with metastatic SGC with a relatively long life expectancy. For patients with AdCC or AcCC and a WHO performance status score of 0-1, an even more prolonged RT schedule for palliation of locoregional disease or symptomatic distant metastases might be considered. Nevertheless, in case of short life expectancy or a WHO performance status of 2-3, a short fractionation schedule is usually preferred.

Oligometastatic disease. For oligometastatic disease, locoregional treatments such as surgery,⁷¹⁻⁷³ radiofrequency ablation⁷⁴ or stereotactic RT⁷⁵ can be considered in selected cases, especially in AdCC. In one study, a prolonged disease-free interval (>36 months) and radical resection were the main prognostic factors in 109 patients with AdCC and lung metastases who underwent metastasectomy.⁷¹

Systemic treatment for recurrent and/or metastatic disease

In case of R/M disease, systemic treatment is challenging but can be urgent, depending on tumour subtype and behaviour. For all types of SGC with distant metastases (71% of patients will present or develop R/M disease), median OS is 15 months and 1-, 3- and 5-year OS rates are 54.5%, 28.4% and 14.8%, respectively.⁷⁶ This, however, varies widely between subtypes.

The rarity of SGC and its extensive heterogeneity hinders large-scale patient accrual in prospective trials. The number of clinical trials evaluating systemic therapy in R/M SGC is low and their interpretation is difficult because most phase II studies include all SGC subtypes, pathological review for correct histopathological subtyping is missing and data on efficacy are not presented by subtype.⁷⁷

An overview of targeted therapies evaluated in SGC is presented in [Supplementary Table S6](https://doi.org/10.1016/j.esmoop.2022.100602), available at <https://doi.org/10.1016/j.esmoop.2022.100602>.

MEC. The reported risk of distant metastasis in MEC is 16% at 10 years.⁷⁸ In R/M MEC, responses with cisplatin alone or in combination with other agents [e.g. cisplatin–adriamycin–cyclophosphamide (CAP) or cisplatin–gemcitabine]

and paclitaxel as monotherapy have been observed in small patient cohorts (three responses on paclitaxel monotherapy in 14 patients in the largest MEC cohort).⁷⁹ The *CRTC1-MAML2* gene fusion, which is commonly present in MECs, causes up-regulation of the epidermal growth factor receptor (EGFR) ligand amphiregulin,⁸⁰ suggesting a potential role for EGFR inhibitors. Reports of clinical benefit with an EGFR inhibitor in patients with MEC are, however, anecdotal and require further investigation.

AdCC. To date, no systemic treatment has been shown to improve OS in patients with R/M AdCC. Metastatic AdCC is generally characterised by multiple locoregional recurrences accompanied by distant metastases in about half of cases. The lung is the most common site of distant spread followed by the lymph nodes, bone, liver, etc. Despite these characteristics, survival of patients with R/M AdCC is generally prolonged, with an OS rate of 40% at 10 years.⁷¹ In this context, active surveillance could be a rational proposal in highly selected patients (asymptomatic, low tumour burden, lung metastases and stable disease). Lung metastasectomy should be considered in patients without other R/M tumour deposits, provided that a complete surgical resection is feasible and disease-free interval from primary diagnosis is >36 months.⁷¹ Systemic treatment should be reserved for patients with progressive and/or symptomatic disease that is not otherwise manageable. A cisplatin-based regimen seems to guarantee the highest response rate: 13% with cisplatin alone and 25% (95% CI 11% to 39%) with CAP.⁸¹ Duration of response ranges widely from 7 to 77 months. Carboplatin seems to have limited activity, and no response has been reported with paclitaxel or gemcitabine.⁸¹ Compounds tailored for actionable targets such as EGFR, KIT and fibroblast growth factor receptor have failed to demonstrate any activity.⁷⁹ Strategies focused on pathogenetic targets seem more promising. Clinical trials are currently evaluating two agents with different strategies: CB103, which targets *NOTCH* oncogene transcription factors (NCT03422679), and AL101, which inhibits gamma secretase (ACCURACY; NCT03691207). Partial response was observed in 15% of patients (6/39) treated with AL101 at 4 mg, and further drug titration is being studied.⁸² Trials targeting *MYB*, the hallmark of AdCC, are underway. A study combining *MYB* DNA vaccination with anti-programmed cell death protein 1 immunotherapy is currently recruiting patients (MYPHISMO; NCT03287427). Antiangiogenic agents (sorafenib, lenvatinib and axitinib) have been investigated in recent years, but response rates did not exceed 15%⁷⁹ (see [Supplementary Table S7](https://doi.org/10.1016/j.esmoop.2022.100602), available at <https://doi.org/10.1016/j.esmoop.2022.100602>). In this context, axitinib was the first agent to demonstrate a significant PFS prolongation compared with placebo in a phase II randomised trial (hazard ratio 0.25, 95% CI 0.14-0.48),⁸³ becoming the new backbone for future trials. The activity of immune checkpoint inhibitors alone is null in patients with R/M AdCC.⁷⁹ Given the disappointing results of systemic treatments, participation in clinical trials is strongly recommended.

AcCC. Distant metastases occur in 19% of patients with AcCC. No data on ChT are available and the role of the *HTN3-MSANTD3* fusion gene (present in 4% of patients) is unknown and not targetable yet. Nevertheless, *NTRK* gene fusion analysis must be carried out in patients with R/M AcCC because secretory carcinoma is often misclassified as AcCC, and tumours with *NTRK* fusion genes respond extremely well to targeted therapy (see below).

Polymorphous adenocarcinoma. The prognosis of patients with polymorphous adenocarcinoma is generally good and distant metastases are rare, reported in only 4.3% of patients at presentation.⁸⁴ No data on ChT or targeted therapy are available.

Adenocarcinoma NOS. CAP, paclitaxel monotherapy and gemcitabine or vinorelbine in combination with cisplatin have led to limited response rates in adenocarcinoma NOS. If the tumour is androgen receptor positive and/or has *HER2* amplification, it is most likely a salivary duct carcinoma and must be treated in the same way as salivary duct carcinoma (see below).⁸⁵

Salivary duct carcinoma. Fifty-four percent of patients with salivary duct carcinoma treated with curative intent will develop locoregional recurrences and/or distant metastases. In patients with distant metastases, spread to lungs (54%) and bones (46%) has been reported most frequently, but a high rate of brain metastasis has also been observed (18%).⁸⁶ Given the dismal prognosis and high prevalence of distant metastasis (also in case of local or locoregional recurrence), systemic therapy is often required. The median OS for patients with R/M disease receiving best supportive care is only 5 months.⁸⁷

Agents targeting androgen receptors and/or *HER2* are promising and are the best studied therapies in patients with salivary duct carcinoma. A prospective phase II trial evaluating the effect of combined androgen blockade with leuprolerin acetate and bicalutamide in 36 patients with SGC (of which 34 were salivary duct carcinoma) demonstrated partial or complete response in 41.7% of patients (95% CI 25.5% to 59.2%) and stable disease in 44.4% (95% CI 27.9% to 61.9%).⁸⁸ Given the low rate of grade 3/4 toxicity, combined androgen blockade plays an important role in the palliative treatment of androgen receptor-positive salivary duct carcinoma. Androgen deprivation therapy (ADT) may also be beneficial in the adjuvant setting. Based on retrospective data, adjuvant ADT results in significantly improved 3-year disease-free survival in patients with stage IVa androgen receptor-positive salivary duct carcinoma [48.2% (95% CI 14.0% to 82.4%) versus 27.7% (95% CI 18.5% to 36.9%) in the control group, which did not receive adjuvant ADT].⁸⁹

In *HER2*-positive salivary duct carcinoma, trastuzumab combined with taxane-based ChT is the best studied regimen, with an overall response rate of 70.2% (95% CI 56.6% to 81.6%) and median OS of 39.7 months (95% CI not reached) reported for trastuzumab—docetaxel in 57 patients with salivary duct carcinoma.⁹⁰ This combination

could potentially be amplified with the addition of another agent targeting *HER2* (e.g. pertuzumab, lapatinib) or, after progressive disease, replacement of trastuzumab with the antibody—drug conjugate trastuzumab—emtansine (T-DM1). An oral presentation at the American Society of Clinical Oncology congress in 2019 emphasised the potential of T-DM1 in *HER2*-amplified SGC, as 9 out of 10 patients (0-3 lines of prior treatment, median of 2) responded to this treatment. Presumably most of these patients had salivary duct carcinoma. Median PFS was not reached after a median follow-up of 12 months.⁹¹ In analogy with the positive results achieved in *HER2*-positive breast cancer by adding pertuzumab to docetaxel—trastuzumab and the cases reported for this combination in salivary duct carcinoma, this triple combination deserves pursuit in clinical studies in salivary duct carcinoma. In patients co-expressing *HER2* and androgen receptors, it is currently unclear whether targeting androgen receptors or *HER2* is the best approach. In case of extensive or rapidly progressive disease, *HER2*-targeting therapy in combination with taxane-based ChT is the reasonable choice over antihormonal therapy, as in breast cancer, but there is no evidence for this approach (expert opinion).

Besides androgen receptors and *HER2*, a number of mutations are observed in lower frequencies in salivary duct carcinoma, which form a genetic landscape highly similar to apocrine breast cancer.⁹² These include mutations in *TP53* (53%-68%), *PIK3CA* (18%-26%), *HRAS* (16%-23%), *BRAF* (4%) and *AKT1* (1.5%). Reports of use of these targets in clinical practice are scarce.⁹³ When these mutations are identified, patients should be preferably treated in basket studies.

The most frequently used ChT regimen in R/M salivary duct carcinoma is carboplatin—paclitaxel.⁷⁹ Although 30%-60% of salivary duct carcinomas demonstrate IHC positivity for programmed death-ligand 1, no phase II data with immune checkpoint inhibitors are available.⁹⁴

Secretory carcinoma. The body of evidence for the efficacy of tropomyosin receptor kinase (TRK) inhibitors (e.g. larotrectinib, entrectinib, repotrectinib, LOXO-195) in patients with secretory carcinoma and *NTRK* gene fusions is expanding.⁹⁵ A recent phase II trial evaluating the efficacy of larotrectinib in *NTRK* fusion-positive patients included 12 patients with secretory carcinoma and reported a response rate of 75%. Median PFS was not reached after a median follow-up of 9.9 months.⁹⁶ Responses in patients with secretory carcinoma have also been observed with entrectinib and repotrectinib.^{97,98} A phase I/II trial evaluating LOXO-195 in second-line treatment is currently recruiting and is open for inclusion of patients with *NTRK* fusion-positive SGC who have previously been treated with a TRK inhibitor and are showing progressive disease, unresponsiveness or intolerance (NCT03215511). Positive IHC staining for TRK generally correlates with *NTRK1* and *NTRK2* fusions, even if specificity is lower for SGCs (52%) compared with other malignant tumours.⁹⁹ For treatment with TRK inhibitors, RNA confirmation is needed.

Other SGC subtypes. For some histological subtypes, little or no clinical evidence is available to make hard recommendations for additional IHC staining or molecular evaluation to identify therapeutic targets. For these subtypes, IHC staining for androgen receptors and evaluation of HER2 expression, preferably by IHC staining and FISH, are advocated. Besides this, use of an NGS panel which includes frequently affected genes in other cancers that are currently targetable with anticancer drugs (e.g. *PIK3CA*, *BRAF*, *NRAS*, *MET*) is suggested. Regarding gene fusions, which are often not present in commercially available panels, it is important to test specifically for *NTRK* gene fusions, as these have great implications for individual patients.

Recommendations

RT

- Re-irradiation with C12 can be considered [IV, B]. Evidence is lacking to support the added value of proton treatment [V, C].
- There is currently no evidence to support the combination of re-irradiation and ChT for primary treatment of SGC [IV, C].

Systemic treatment

- In case of R/M disease, consider sequencing (NGS) of the tumour [V, C].
- Participation in clinical trials is strongly recommended [V, C].

AdCC

- In case of activated *NOTCH* mutation, participation in a *NOTCH* inhibitor clinical study is recommended, if possible [V, B].
- In case of only lung metastases without local recurrence, a watch-and-wait strategy is recommended until complaints or rapid growth (local treatment of lung metastases could be considered in selected cases) [III, B].
- In case of liver and/or bone involvement, there is a lower threshold to start (often more aggressive) systemic treatment [IV, C].
- When starting systemic treatment, consider angiogenesis inhibitors [III, C] or platinum-based ChT (i.e. CAP or doxorubicin—cisplatin) [III, B].

Salivary duct carcinoma

- In case of R/M disease, start systemic treatment immediately [III, B].
- In case of androgen receptor positivity (>70% by IHC) consider ADT (combined antihormonal or antiandrogen as a single agent) [III, B; ESCAT score: II-B].
- In case of HER2 positivity (IHC score 3+ or FISH positivity) consider docetaxel—trastuzumab or T-DM1 [III, B; ESCAT score: II-B; not European Medicines Agency (EMA) or Food and Drug Administration (FDA) approved].
- For systemic ChT, carboplatin—paclitaxel should be considered [III, B].

Secretory carcinoma

- In patients with secretory carcinoma and *NTRK* gene fusions, treatment with a TRK inhibitor (entrectinib or

larotrectinib) is recommended [III, A; ESMO-Magnitude of Clinical Benefit Scale (MCBS) v1.1 score: 3; ESCAT score: I-C].

Other SGC

- Consider platinum-based palliative ChT [III, B].

FOLLOW-UP, LONG-TERM IMPLICATIONS AND SURVIVORSHIP

Follow-up is designed to detect R/M disease. Strict rules cannot be provided in the absence of formal studies. Recommended follow-up may include MRI and chest CT. There is no consensus on the value of positron emission tomography for assessing local recurrence compared with conventional imaging.¹⁰⁰

Further information on follow-up, long-term implications and survivorship is provided in Section 6 of the [Supplementary Material](https://doi.org/10.1016/j.esmoop.2022.100602), available at <https://doi.org/10.1016/j.esmoop.2022.100602>.

Recommendations

- Follow-up may include the use of MRI for locoregional recurrence and chest CT for lung metastases [V, C].
- In AdCC, locoregional imaging (preferably head and neck MRI with contrast agent administration) is suggested every 3-4 months for the first 2 years, every 6 months from the third to the fifth year and then on an annual basis thereafter [V, C]. A lung CT at least annually should also be considered.
- For other patients with SGC who do not have any evidence of disease activity, regular scans 1-2 times per year are suggested for the first 1-2 years, before moving to less frequent scans. Patients with residual/recurrent or metastatic disease should be scanned more regularly (i.e. 2-4 times per year), but when a low growth rate is present, the imaging frequency can be decreased [V, C].
- MRI scans are the best imaging tool for locoregional recurrent disease [V, C].
- A good multidisciplinary recovery programme is needed for every patient with SGC [V, B].

METHODOLOGY

This Clinical Practice Guideline (CPG) was developed in accordance with the ESMO standard operating procedures for CPG development (<http://www.esmo.org/Guidelines/ESMO-Guidelines-Methodology>). The relevant literature has been selected by the expert authors. An ESCAT table with ESCAT scores is included in [Supplementary Table S3](https://doi.org/10.1016/j.esmoop.2022.100602), available at <https://doi.org/10.1016/j.esmoop.2022.100602>. ESCAT scores have been defined by the authors and validated by the ESMO Translational Research and Precision Medicine Working Group.¹⁰¹ An ESMO-MCBS table with ESMO-MCBS scores is included in [Supplementary Table S8](https://doi.org/10.1016/j.esmoop.2022.100602), available at <https://doi.org/10.1016/j.esmoop.2022.100602>. ESMO-MCBS v1.1¹⁰² was used to calculate scores for new therapies/indications approved by the EMA

or FDA (<https://www.esmo.org/Guidelines/ESMO-MCBS>). The scores have been calculated by the ESMO-MCBS Working Group and validated by the ESMO Guidelines Committee. The FDA/EMA or other regulatory body approval status of new therapies/indications is reported at the time of writing this CPG. Levels of evidence and grades of recommendation have been applied using the system shown in [Supplementary Table S9](#), available at <https://doi.org/10.1016/j.esmoop.2022.100602>.^{103,104} Statements without grading were considered justified standard clinical practice by the authors. Future updates to this CPG will be published on [esmo.org](https://www.esmo.org) as a Living Guideline version or an eUpdate, to be made available at: <https://www.esmo.org/guidelines/head-and-neck-cancers/salivary-gland-cancer>.

ACKNOWLEDGEMENTS

Manuscript editing support was provided by Louise Green and Jennifer Lamarre (ESMO Guidelines staff) and Angela Corstorphine and Sian-Marie Lucas of Kstorfin Medical Communications Ltd (KMC); this support was funded by ESMO. Nathan Cherny, Chair of the ESMO-MCBS Working Group, Urani Dafni, ESMO-MCBS Working Group Member/Frontier Science Foundation Hellas and Giota Zygoura of Frontier Science Foundation Hellas provided review and validation of the ESMO-MCBS scores. Nicola Latino (ESMO Scientific Affairs staff) provided coordination and support of the ESMO-MCBS scores and Angela Corstorphine and Sian-Marie Lucas of KMC provided medical writing and editing support in the preparation of the ESMO-MCBS table; this support was funded by ESMO. Joaquin Mateo (Chair of the ESMO Translational Research and Precision Medicine Working Group) and Dr Svetlana Jezdic (ESMO Medical Affairs Advisor) provided validation support for ESCAT scores.

FUNDING

No external funding has been received for the preparation of this guideline. Production costs have been covered by ESMO from central funds.

DISCLOSURE

VVP reports fees paid to his institute as an invited speaker from Atos Medical, Bristol Myers Squibb (BMS) and Ethicon – Johnson & Johnson and non-remunerated roles as a member of the Board of Directors and Secretary General of the Multidisciplinary Salivary Gland Society. BB reports personal fees for advisory board participation from Merck Sharp & Dohme (MSD) and Merck, personal fees as an invited speaker for Sanofi and fees paid to his institute as local Principal Investigator (PI) for BMS. LDL reports personal fees for advisory board membership of Eli Lilly, Merck Serono and MSD, personal fees as an invited speaker for Biogen, Eisai, Ipsen, Sanofi Regeneron and SunPharma and fees paid to her institute as local PI for Eisai. She also reports non-remunerated leadership roles with the Endocrine Tumour Group and as an Officer for the Scientific Chairs Council of European Organisation for Research and Treatment of Cancer (EORTC), affiliate for the Italian Association

of Medical Oncology (AIOM) and the Multidisciplinary Salivary Gland Society (MSGs) and an advisory role for Associazione Italiana Oncologia Cervico Cefalica (AIOCC). JH reports personal fees from stocks/shares from RiverD/MarginGuide. EK reports personal fees for full- or part-time employment as the Consumer Lead for the National Cancer Research Institute (NCRI) and a non-remunerated role as a member of the Board of Directors of Salivary Gland Cancer UK. CE reports personal fees for advisory board membership of BMS, MSD, Merck Serono and Innate Pharma, fees paid to her institute for advisory board membership for F-star Therapeutics and institutional funding as a local or coordinating PI for BMS, AstraZeneca, ISA Pharmaceuticals, MSD, Debiopharma, Ayala and Novartis. JPM reports fees paid to his institute for advisory board participation from ALX Oncology, AstraZeneca (Steering Committee member), Bayer, BMS, Boehringer Ingelheim, Cue Biopharma, DeBio, F-star Therapeutics, Incyte, Innate, Janssen, Johnson & Johnson, Merck Serono, MSD (uncompensated), Nanobiotix, Nektar Therapeutics, Novartis, Pfizer and Roche; travel support from Gilead; institutional research support as local or coordinating PI from AbbVie, Amgen, Bayer, Boehringer Ingelheim, Ceylad Oncology, eTheRNA, GlaxoSmithKline, Incyte, iTeos Therapeutics, Janssen, Johnson & Johnson, Kura Oncology, Lilly, MSD (Steering Committee member), Novartis, Pfizer, Roche, Sanofi-Aventis and Merck Serono. He also reports a non-remunerated leadership role as Chair with the EORTC Head and Neck Group. All other authors have declared no conflicts of interest.

REFERENCES

1. Ferlay J, Ervik M, Lam F, et al. *Global Cancer Observatory: Cancer Today*. Lyon, France: International Agency for Research on Cancer. Available at <https://gco.iarc.fr/today>. Accessed February 14, 2022.
2. RARECARENet. Information Network on Rare Cancers. Available at <http://rarecarenet.istitutotumori.mi.it/>. Accessed February 14, 2022.
3. Radoi L, Barul C, Menvielle G, et al. Risk factors for salivary gland cancers in France: results from a case-control study, the ICARE study. *Oral Oncol*. 2018;80:56-63.
4. Lin HH, Limesand KH, Ann DK. Current state of knowledge on salivary gland cancers. *Crit Rev Oncog*. 2018;23(3-4):139-151.
5. Cong X. Air pollution from industrial waste gas emissions is associated with cancer incidences in Shanghai, China. *Environ Sci Pollut Res Int*. 2018;25(13):13067-13078.
6. Sawabe M, Ito H, Takahara T, et al. Heterogeneous impact of smoking on major salivary gland cancer according to histopathological subtype: a case-control study. *Cancer*. 2018;124(1):118-124.
7. Boukheris H, Curtis RE, Land CE, et al. Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States. *Cancer Epidemiol Biomarkers Prev*. 2009;18(11):2899-2906.
8. Alvi S, Chudek D, Limaie F. *Cancer, Parotid*. Treasure Island, FL: StatPearls Publishing; 2020.
9. Bradley PJ, McGurk M. Incidence of salivary gland neoplasms in a defined UK population. *Br J Oral Maxillofac Surg*. 2013;51(5):399-403.
10. Gatta G, Capocaccia R, Botta L, et al. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet – a population-based study. *Lancet Oncol*. 2017;18(8):1022-1039.
11. El Naggar AK, Chan JK, Grandis JR, et al. *World Health Organization (WHO) Classification of Head and Neck Tumours*. 4th ed. Lyon, France: IARC Press; 2017.

12. Faquin W, Rossi ED. *The Milan System for Reporting Salivary Gland Cytopathology*. New York, NY: Springer; 2018.
13. Farahani SJ, Baloch Z. Retrospective assessment of the effectiveness of the Milan system for reporting salivary gland cytology: a systematic review and meta-analysis of published literature. *Diagn Cytopathol*. 2019;47(2):67-87.
14. Kim BY, Hyeon J, Ryu G, et al. Diagnostic accuracy of fine needle aspiration cytology for high-grade salivary gland tumors. *Ann Surg Oncol*. 2013;20(7):2380-2387.
15. Howlett DC, Triantafyllou A. Evaluation: fine needle aspiration cytology, ultrasound-guided core biopsy and open biopsy techniques. *Adv Otorhinolaryngol*. 2016;78:39-45.
16. Cho J, Kim J, Lee JS, et al. Comparison of core needle biopsy and fine-needle aspiration in diagnosis of malignant salivary gland neoplasm: systematic review and meta-analysis. *Head Neck*. 2020;42(10):3041-3050.
17. Romano EB, Wagner JM, Alleman AM, et al. Fine-needle aspiration with selective use of core needle biopsy of major salivary gland tumors. *Laryngoscope*. 2017;127(11):2522-2527.
18. Ihrler S, Agaimy A, Guntinas-Lichius O, et al. Why is the histomorphological diagnosis of tumours of minor salivary glands much more difficult? *Histopathology*. 2021;79(5):779-790.
19. Seethala RR. An update on grading of salivary gland carcinomas. *Head Neck Pathol*. 2009;3(1):69-77.
20. Skalova A, Stenman G, Simpson RHW, et al. The role of molecular testing in the differential diagnosis of salivary gland carcinomas. *Am J Surg Pathol*. 2018;42(2):e11-e27.
21. O'Sullivan B. Major salivary glands. In: Brierley JD, Gospodarowicz MK, Wittekind C, editors. *UICC TNM Classification of Malignant Tumours*. 8th ed. Oxford, UK: Wiley-Blackwell; 2017.
22. Lombardi D, Tomasoni M, Paderno A, et al. The impact of nodal status in major salivary gland carcinoma: a multicenter experience and proposal of a novel N-classification. *Oral Oncol*. 2021;112:105076.
23. Seethala RR, Altemani A, Ferris RL, et al. Data set for the reporting of carcinomas of the major salivary glands: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. *Arch Pathol Lab Med*. 2019;143(5):578-586.
24. Lombardi D, McGurk M, Vander Poorten V, et al. Surgical treatment of salivary malignant tumors. *Oral Oncol*. 2017;65:102-113.
25. Sood S, McGurk M, Vaz F. Management of salivary gland tumours: United Kingdom National Multidisciplinary Guidelines. *J Laryngol Otol*. 2016;130(52):S142-S149.
26. Dillon PM, Chakraborty S, Moskaluk CA, et al. Adenoid cystic carcinoma: a review of recent advances, molecular targets, and clinical trials. *Head Neck*. 2016;38(4):620-627.
27. Renkonen S, Sayed F, Keski-Santti H, et al. Reconstruction of facial nerve after radical parotidectomy. *Acta Otolaryngol*. 2015;135(10):1065-1069.
28. Bollig CA, Wang K, Llerena P, et al. National analysis of oropharyngeal salivary gland malignancies treated with transoral robotic surgery. *Otolaryngol Head Neck Surg*. 2022;166(5):886-893.
29. Hay AJ, Migliacci J, Karassawa Zanon D, et al. Minor salivary gland tumors of the head and neck-Memorial Sloan Kettering experience: incidence and outcomes by site and histological type. *Cancer*. 2019;125(19):3354-3366.
30. Goel AN, Badran KW, Braun APG, et al. Minor salivary gland carcinoma of the oropharynx: a population-based analysis of 1426 patients. *Otolaryngol Head Neck Surg*. 2018;158(2):287-294.
31. Han MW, Cho KJ, Roh JL, et al. Patterns of lymph node metastasis and their influence on outcomes in patients with submandibular gland carcinoma. *J Surg Oncol*. 2012;106(4):475-480.
32. Aro K, Tarkkanen J, Saat R, et al. Submandibular gland cancer: specific features and treatment considerations. *Head Neck*. 2018;40(1):154-162.
33. Vander Poorten VL, Balm AJ, Hilgers FJ, et al. Prognostic factors for long term results of the treatment of patients with malignant submandibular gland tumors. *Cancer*. 1999;85(10):2255-2264.
34. International Head and Neck Scientific Group. Cervical lymph node metastasis in adenoid cystic carcinoma of the major salivary glands. *J Laryngol Otol*. 2017;131(2):96-105.
35. Yoo SH, Roh JL, Kim SO, et al. Patterns and treatment of neck metastases in patients with salivary gland cancers. *J Surg Oncol*. 2015;111(8):1000-1006.
36. Stennert E, Kisner D, Jungehulsing M, et al. High incidence of lymph node metastasis in major salivary gland cancer. *Arch Otolaryngol Head Neck Surg*. 2003;129(7):720-723.
37. Guzzo M, Locati LD, Prott FJ, et al. Major and minor salivary gland tumors. *Crit Rev Oncol Hematol*. 2010;74(2):134-148.
38. Klusmann JP, Ponert T, Mueller RP, et al. Patterns of lymph node spread and its influence on outcome in resectable parotid cancer. *Eur J Surg Oncol*. 2008;34(8):932-937.
39. Ali S, Palmer FL, DiLorenzo M, et al. Treatment of the neck in carcinoma of the parotid gland. *Ann Surg Oncol*. 2014;21(9):3042-3048.
40. Armstrong JG, Harrison LB, Thaler HT, et al. The indications for elective treatment of the neck in cancer of the major salivary glands. *Cancer*. 1992;69(3):615-619.
41. Frankenthaler RA, Byers RM, Luna MA, et al. Predicting occult lymph node metastasis in parotid cancer. *Arch Otolaryngol Head Neck Surg*. 1993;119(5):517-520.
42. Regis De Brito Santos I, Kowalski LP, Cavalcante De Araujo V, et al. Multivariate analysis of risk factors for neck metastases in surgically treated parotid carcinomas. *Arch Otolaryngol Head Neck Surg*. 2001;127(1):56-60.
43. Stenner M, Molls C, Luers JC, et al. Occurrence of lymph node metastasis in early-stage parotid gland cancer. *Eur Arch Otorhinolaryngol*. 2012;269(2):643-648.
44. Kawata R, Koutetsu L, Yoshimura K, et al. Indication for elective neck dissection for N0 carcinoma of the parotid gland: a single institution's 20-year experience. *Acta Otolaryngol*. 2010;130(2):286-292.
45. Lau VH, Aouad R, Farwell DG, et al. Patterns of nodal involvement for clinically N0 salivary gland carcinoma: refining the role of elective neck irradiation. *Head Neck*. 2014;36(10):1435-1439.
46. Vander Poorten V, Triantafyllou A, Thompson LD, et al. Salivary acinic cell carcinoma: reappraisal and update. *Eur Arch Otorhinolaryngol*. 2016;273(11):3511-3531.
47. Terhaard CH, Lubsen H, Rasch CR, et al. The role of radiotherapy in the treatment of malignant salivary gland tumors. *Int J Radiat Oncol Biol Phys*. 2005;61(1):103-111.
48. Chen AM, Garcia J, Lee NY, et al. Patterns of nodal relapse after surgery and postoperative radiation therapy for carcinomas of the major and minor salivary glands: what is the role of elective neck irradiation? *Int J Radiat Oncol Biol Phys*. 2007;67(4):988-994.
49. Herman MP, Werning JW, Morris CG, et al. Elective neck management for high-grade salivary gland carcinoma. *Am J Otolaryngol*. 2013;34(3):205-208.
50. Zbaren P, Schubach J, Nuyens M, et al. Elective neck dissection versus observation in primary parotid carcinoma. *Otolaryngol Head Neck Surg*. 2005;132(3):387-391.
51. Nobis CP, Rohleder NH, Wolff KD, et al. Head and neck salivary gland carcinomas—elective neck dissection, yes or no? *J Oral Maxillofac Surg*. 2014;72(1):205-210.
52. Olsen KD, Moore EJ. Deep lobe parotidectomy: clinical rationale in the management of primary and metastatic cancer. *Eur Arch Otorhinolaryngol*. 2014;271(5):1181-1185.
53. Vander Poorten V, Hunt J, Bradley PJ, et al. Recent trends in the management of minor salivary gland carcinoma. *Head Neck*. 2014;36(3):444-455.
54. Hellquist H, Skalova A, Barnes L, et al. Cervical lymph node metastasis in high-grade transformation of head and neck adenoid cystic carcinoma: a collective international review. *Adv Ther*. 2016;33(3):357-368.
55. Atallah S, Moya-Plana A, Malard O, et al. Should a neck dissection be performed on patients with cN0 adenoid cystic carcinoma? A REFCOR propensity score matching study. *Eur J Cancer*. 2020;130:250-258.
56. Ellis MA, Graboyes EM, Day TA, et al. Prognostic factors and occult nodal disease in mucoepidermoid carcinoma of the oral cavity and oropharynx: an analysis of the National Cancer Database. *Oral Oncol*. 2017;72:174-178.

57. Roh JL, Choi SH, Lee SW, et al. Carcinomas arising in the submandibular gland: high propensity for systemic failure. *J Surg Oncol*. 2008;97(6):533-537.
58. Salivary glands. In: Halperin EC, Wazer DE, Perez CA, Brady LW, editors. *Perez & Brady's Principles and Practice of Radiation Oncology*. 7th ed. Philadelphia, PA: Wolters Kluwer Health; 2018.
59. Armstrong K, Ward J, Hughes NM, et al. Guidelines for clinical target volume definition for perineural spread of major salivary gland cancers. *Clin Oncol (R Coll Radiol)*. 2018;30(12):773-779.
60. Cheraghlou S, Kuo P, Mehra S, et al. Adjuvant therapy in major salivary gland cancers: analysis of 8580 patients in the National Cancer Database. *Head Neck*. 2018;40(7):1343-1355.
61. Mifsud MJ, Tanvetyanon T, McCaffrey JC, et al. Adjuvant radiotherapy versus concurrent chemoradiotherapy for the management of high-risk salivary gland carcinomas. *Head Neck*. 2016;38(11):1628-1633.
62. Gebhardt BJ, Ohr JP, Ferris RL, et al. Concurrent chemoradiotherapy in the adjuvant treatment of high-risk primary salivary gland malignancies. *Am J Clin Oncol*. 2018;41(9):888-893.
63. Amini A, Waxweiler TV, Brower JV, et al. Association of adjuvant chemoradiotherapy vs radiotherapy alone with survival in patients with resected major salivary gland carcinoma: data from the National Cancer Data Base. *JAMA Otolaryngol Head Neck Surg*. 2016;142(11):1100-1110.
64. Cerda T, Sun XS, Vignot S, et al. A rationale for chemoradiation (vs radiotherapy) in salivary gland cancers? On behalf of the REFCOR (French rare head and neck cancer network). *Crit Rev Oncol Hematol*. 2014;91(2):142-158.
65. Pelak MJ, Walser M, Bachtiaji B, et al. Clinical outcomes of head and neck adenoid cystic carcinoma patients treated with pencil beam-scanning proton therapy. *Oral Oncol*. 2020;107:104752.
66. Vischioni B, Dhanireddy B, Severo C, et al. Reirradiation of salivary gland tumors with carbon ion radiotherapy at CNAO. *Radiother Oncol*. 2020;145:172-177.
67. Hayashi K, Koto M, Ikawa H, et al. Feasibility of re-irradiation using carbon ions for recurrent head and neck malignancies after carbon-ion radiotherapy. *Radiother Oncol*. 2019;136:148-153.
68. Jensen AD, Poulakis M, Nikoghosyan AV, et al. Re-irradiation of adenoid cystic carcinoma: analysis and evaluation of outcome in 52 consecutive patients treated with raster-scanned carbon ion therapy. *Radiother Oncol*. 2015;114(2):182-188.
69. Lok BH, Jiang G, Gutiontov S, et al. Palliative head and neck radiotherapy with the RTOG 8502 regimen for incurable primary or metastatic cancers. *Oral Oncol*. 2015;51(10):957-962.
70. Al-mamgani A, Tans L, Van Rooij PH, et al. Hypofractionated radiotherapy denoted as the "Christie scheme": an effective means of palliating patients with head and neck cancers not suitable for curative treatment. *Acta Oncol*. 2009;48(4):562-570.
71. Girelli L, Locati L, Galeone C, et al. Lung metastasectomy in adenoid cystic cancer: is it worth it? *Oral Oncol*. 2017;65:114-118.
72. Locati LD, Guzzo M, Bossi P, et al. Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary gland. *Oral Oncol*. 2005;41(9):890-894.
73. Bobbio A, Copelli C, Ampollini L, et al. Lung metastasis resection of adenoid cystic carcinoma of salivary glands. *Eur J Cardiothorac Surg*. 2008;33(5):790-793.
74. Bergamini C, Cavalieri S, Cascella T, et al. Local therapies for liver metastases of rare head and neck cancers: a monoinstitutional case series. *Tumori*. 2021;107(3):188-195.
75. Franzese C, Ingargiola R, Tomatis S, et al. Metastatic salivary gland carcinoma: a role for stereotactic body radiation therapy? A study of AIRO-Head and Neck working group. *Oral Dis*. 2022;28(2):345-351.
76. Nam SJ, Roh JL, Cho KJ, et al. Risk factors and survival associated with distant metastasis in patients with carcinoma of the salivary gland. *Ann Surg Oncol*. 2016;23(13):4376-4383.
77. Lassche G, van Boxtel W, Ligtnerberg MJL, et al. Advances and challenges in precision medicine in salivary gland cancer. *Cancer Treat Rev*. 2019;80:101906.
78. Terhaard CH, Lubsen H, Van der Tweel I, et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch Head and Neck Oncology Cooperative Group. *Head Neck*. 2004;26(8):681-692.
79. Alfieri S, Granata R, Bergamini C, et al. Systemic therapy in metastatic salivary gland carcinomas: a pathology-driven paradigm? *Oral Oncol*. 2017;66:58-63.
80. Chen Z, Chen J, Gu Y, et al. Aberrantly activated AREG-EGFR signaling is required for the growth and survival of CRTC1-MAML2 fusion-positive mucoepidermoid carcinoma cells. *Oncogene*. 2014;33(29):3869-3877.
81. Laurie SA, Ho AL, Fury MG, et al. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. *Lancet Oncol*. 2011;12(8):815-824.
82. Ferrarotto R, Wirth LJ, Muzaffar J, et al. 919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut). *Ann Oncol*. 2020;31(suppl 4):S663.
83. Kang EJ, Ahn MJ, Ock CY, et al. Randomized phase II study of axitinib versus observation in patients with recurrent or metastatic adenoid cystic carcinoma. *Clin Cancer Res*. 2021;27(19):5272-5279.
84. Vander Poorten V, Triantafyllou A, Skaloja A, et al. Polymorphous adenocarcinoma of the salivary glands: reappraisal and update. *Eur Arch Otorhinolaryngol*. 2018;275(7):1681-1695.
85. Locati LD, Perrone F, Losa M, et al. Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). *Oral Oncol*. 2009;45(11):986-990.
86. Uijen MJM, Lassche G, van Engen-van Grunsven ACH, et al. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: a systematic review. *Cancer Treat Rev*. 2020;89:102069.
87. Boon E, van Boxtel W, Buter J, et al. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: a nationwide case series of 35 patients in The Netherlands. *Head Neck*. 2018;40(3):605-613.
88. Fushimi C, Tada Y, Takahashi H, et al. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. *Ann Oncol*. 2018;29(4):979-984.
89. van Boxtel W, Locati LD, van Engen-van Grunsven ACH, et al. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma. *Eur J Cancer*. 2019;110:62-70.
90. Takahashi H, Tada Y, Saotome T, et al. Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. *J Clin Oncol*. 2019;37(2):125-134.
91. Li BT, Shen R, Offin M, et al. Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): results from a phase II basket trial. *J Clin Oncol*. 2019;37(suppl 15):6001.
92. Dalin MG, Desrichard A, Katabi N, et al. Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer. *Clin Cancer Res*. 2016;22(18):4623-4633.
93. Lin VTG, Nabell LM, Spencer SA, et al. First-line treatment of widely metastatic BRAF-mutated salivary duct carcinoma with combined BRAF and MEK inhibition. *J Natl Compr Canc Netw*. 2018;16(10):1166-1170.
94. Xu B, Jungbluth AA, Frosina D, et al. The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma. *Histopathology*. 2019;75(5):672-682.
95. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. *Nat Rev Clin Oncol*. 2018;15(12):731-747.
96. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. *N Engl J Med*. 2018;378(8):731-739.
97. Drilon A, Li G, Dogan S, et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). *Ann Oncol*. 2016;27(5):920-926.

98. Drilon A, Ou SI, Cho BC, et al. Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent-front mutations. *Cancer Discov.* 2018;8(10):1227-1236.
99. Solomon JP, Linkov I, Rosado A, et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. *Mod Pathol.* 2020;33(1):38-46.
100. Broski SM, Johnson DR, Packard AT, et al. 18F-fluorodeoxyglucose PET/computed tomography: head and neck salivary gland tumors. *PET Clin.* 2022;17(2):249-263.
101. Mateo J, Chakravarty D, Dienstmann R, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). *Ann Oncol.* 2018;29(9):1895-1902.
102. Cherny NI, Dafni U, Bogaerts J, et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. *Ann Oncol.* 2017;28(10):2340-2366.
103. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. *Clin Infect Dis.* 2001;33(2):139-144.
104. Gross PA, Barrett TL, Dellinger EP, et al. Purpose of quality standards for infectious diseases. Infectious Diseases Society of America. *Clin Infect Dis.* 1994;18(3):421.